期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤治疗药物帕比司他的临床研究进展 被引量：1

Research progress of panobinostat on multiple myeloma treatment
原文传递
导出
摘要 多发性骨髓瘤(MM)是一种血液系统常见的恶性肿瘤,目前仍无治愈方法且复发率很高。帕比司他(panobinostat)是一种组蛋白去乙酰化酶抑制剂(HDACi),用于治疗MM。本文从HDACi的作用机制与帕比司他的不良反应总结帕比司他对MM的临床疗效。 Multiple myeloma （MM） is a common malignant blood tumor. Meantime, there is still no cure method and its recurrence rate is very high. Panobinostat is a histone deacetylase inhibitor （HDACi）, which is used in MM treatment. This review summarizes the panobinostat used in MM treatmentjncluding its action mechanism against HDACi and its adverse reactions.
作者 常新驰 倪娜 曾训庭 石催催 赵宇晗 陈燕
机构地区 中国医药工业研究总院药物临床研究中心 上海瀛科隆医药开发有限公司
出处 《世界临床药物》 CAS 2018年第2期I0003-I0007,共5页 World Clinical Drug
关键词 多发性骨髓瘤(MM) 组蛋白去乙酰化酶抑制剂(HDACi) 帕比司他 multiple myeloma （MM） histone deacetylase inhibitors （HDACi） panobinostat
分类号 R551.3 [医药卫生—血液循环系统疾病] R979.19 [医药卫生—药品]
  • 相关文献

参考文献3

二级参考文献24

  • 1Mateos MV, Hemandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma[J]. N EnglJ Med, 2013, 369(5):438-447.
  • 2Rajkumar SV, Larson D, Kyle RA.Diagnosis of smoldering multi- ple myeloma[J]. N EnglJ Med, 2011, 365(5):474-475.
  • 3Korthals M, Sehnke N, Kronenwett R, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma[J]. Biol Blood Marrow Transplant, 2013, 19(7): 1109-1115.
  • 4Iwama K, Chihara D, Tsuda K, et al. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favor- able outcome in patients with multiple myeloma[K]. EurJ Haematol, 2013, 90(2):134-141.
  • 5Bradwell A, Harding S, Fourrier N, et al. Prognostic utility of intact immunoglobulin Ig'kappa/Ig'lambda ratios in multiple myeloma pa- tients[J]. Leukemia,2013, 27(1):202-207.
  • 6Corso A, Galli M, Mangiacavalli S, et al. Response-adjusted ISS (RalSS) is a simple and reliable prognostic scoring system for pre- dicting progression-free survival in transplanted patients with mul- tiple myeloma[J]. AmJ Hematol, 2012, 87(2):150-154.
  • 7Liu D, Lin P, Hu Y, et al. Immunophenotypic heterogeneity of nor- real plasma cells: comparison with minimal residual plasma cell my- eloma[J].J Clin Pathol,2012, 65(9):823-829.
  • 8Avet-Loiseau H, Durie BG, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collabora- tive project[J]. Leukemia, 2013, 27(3):711-717.
  • 9Waheed S, ShaughnessyJD, van Rhee F, et al. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols[J]. Cancer, 2011, 117(5):1001-1009.
  • 10Mikhael JR, Dingli D, Roy V, et al. Management of newly diag- nosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013[J]. Mayo Clin Proc, 2013, 88(4):360-376.

共引文献33

同被引文献3

引证文献1

二级引证文献3

世界临床药物
2018年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部